A drug‐resistant variant of topoisomerase IIα in human HL‐60 cells exhibits alterations in catalytic pH optimum, DNA binding and sub‐nuclear distribution
- 1 December 1993
- journal article
- Published by Wiley in European Journal of Biochemistry
- Vol. 218 (2) , 575-584
- https://doi.org/10.1111/j.1432-1033.1993.tb18411.x
Abstract
Anion-exchange chromatography of partially purified human HL-60 topoisomerase II resolves the known alpha (170 kDa) and beta (180 kDa) isoenzymes at 150 mM NaCl and 230 mM NaCl, respectively. An additional topoisomerase II fraction was eluted by > 300 mM NaCl. It could be identified by Western blotting as a late-eluting variant of topoisomerase II alpha, which is functionally altered as compared to the early-eluting form, having the following properties: a shift in the catalytic optimum to pH 9; increased stability in DNA complex formation; approximately 100-fold resistance to orthovanadate; approximately 1000-fold resistance to the cytostatic substances N-[4-(9-acridinylamino)-3-methoxyphenyl]-methanesulphonamide (amsacrine) and the podophyllotoxin etoposide (VP 16). 80% of the late-eluting topoisomerase II alpha could be captured by SDS on calf thymus DNA without further enhancement by drugs. In contrast, the early-eluting topoisomerase II alpha exhibits 10% complex formation with SDS alone, and an increase to 90% complex formation in the presence of drugs. A HL-60 subline (HL-60/R), approximately 1000-fold resistant to etoposide and amsacrine, has equivalent proportions of topoisomerase II alpha and topoisomerase II beta and similar levels of both isoenzymes, as compared to the drug-sensitive HL-60/WT cells. However, determination of the cellular levels of the early-eluting and late-eluting forms of topoisomerase II alpha revealed that the HL-60/R cell line contains approximately 80% of the late-eluting topoisomerase II alpha, whereas the sensitive HL-60/WT cell line contains only 15-20% of this form. The nuclear distribution of the two forms also differs. Sensitive HL-60/WT cells show a diffuse nuclear distribution but in resistant cells the distribution is localized in the nucleoli. Apparently two functionally distinct subforms of topoisomerase II alpha coexist in drug-sensitive and drug-resistant HL-60 cells and changes in their relative levels affect the cellular sensitivity to topoisomerase-II-targeting drugs.Keywords
This publication has 41 references indexed in Scilit:
- Topoisomerase II function detected as protein-DNA complexes in two sublines of HL-60 cellsToxicology Letters, 1993
- Multiple chromosomal populations of topoisomerase II detected in vivo by time-lapse, three-dimensional wide-field microscopyCell, 1993
- Localization of DNA Topoisomerase II in Chinese Hamster Fibroblasts by Confocal and Electron MicroscopyExperimental Cell Research, 1993
- Monoclonal antibodies to human DNA topoisomerase I and the two isoforms of DNA topoisomerase II: 170- and 180-kDa isozymesExperimental Cell Research, 1992
- The 180-kDa isoform of topoisomerase II is localized in the nucleolus and belongs to the structural elements of the nucleolar remnantExperimental Cell Research, 1992
- Two independent amsacrine-resistant human myeloid leukemia cell lines share an identical point mutation in the 170 kDa form of human topoisomerase IIJournal of Molecular Biology, 1992
- Growth state and cell cycle dependent phosphorylation of DNA topoisomerase II in Swiss 3T3 cellsBiochemistry, 1992
- Association of topoisomerase II with the hepatoma cell nuclear matrix: The role of intermolecular disulfide bond formationExperimental Cell Research, 1991
- Purification and characterization of type II DNA topoisomerase from mouse FM3A cells: phosphorylation of topoisomerase II and modification of its activityBiochemistry, 1990
- Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase IIBiochemistry, 1989